ABSTRACT
To evaluate the safety and effectiveness of recombinant human follicle-stimulating hormone (rhFSH [Follitrope™]) in infertile women undergoing in vitro fertilization (IVF). To identify predictors of ovarian response that induce optimal clinical outcomes. This multicenter prospective study enrolled infertile women who were scheduled to undergo IVF after ovarian stimulation with rhFSH (Follitrope™) following the gonadotropin-releasing hormone (GnRH) agonist or GnRH antagonist protocol. Predictive factors for ovarian response were identified in the GnRH antagonist group based on the number of oocytes retrieved. A total of 516 infertile women were enrolled, among whom 136 (except one who withdrew before administration) received rhFSH using the GnRH agonist protocol and 379 using the antagonist protocol. The mean number of oocytes retrieved was 13.4 in the GnRH agonist group and 13.6 in the GnRH antagonist group. The clinical pregnancy rates were 32.3% (30/93) and 39.9% (115/288) in the GnRH agonist and antagonist groups, respectively. The incidence of ovarian hyperstimulation syndrome was 1.8% and 3.4% in the GnRH agonist and antagonist groups, respectively. No other significant safety risks associated with rhFSH administration were identified. Body mass index, basal serum FSH and anti-Müllerian hormone levels, and antral follicle count were identified as predictors of ovarian response by multiple regression with backward elimination, and the final regression model accounted for 26.5% of the response variability. In real-world practice, rhFSH (Follitrope™) is safe and effective in inducing ovarian stimulation in infertile women. Patient characteristics identified as predictors can be considered to be highly related to optimal clinical outcomes.
Subject(s)
Infertility, Female , Pregnancy , Female , Humans , Prospective Studies , Gonadotropin-Releasing Hormone , Follicle Stimulating Hormone, Human , Fertilization in Vitro/methods , Ovulation Induction/methods , Pregnancy Rate , Follicle Stimulating HormoneABSTRACT
The complete chloroplast (cp) genome sequence of Actinidia rufa was determined by next-generation sequencing in this study. The whole cp genome was 156,543 bp in length, containing a large single-copy (LSC) of 88,435 bp and a small single-copy (SSC) region of 20,307 bp, which was separated by a pair of 23,900 bp inverted repeat (IR) regions. The genome contained 131 genes, including 84 protein-coding genes, 39 tRNA genes, 8 ribosomal RNA genes. Two events were found in the Actinidiaceae chloroplast genome. One was the deletion of the clpP gene and the other was the trnfM-CAU gene in the same direction in LSC region. The phylogenetic position of A. rufa was closely clustered with A. chinensis, A. deliciosa as sister species.